Medicare Enrolled
Dr. David Barrera, DO
Hematology & Oncology · Fort Worth, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Barrera from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Barrera?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Barrera
Dr. David Barrera is a hematology & oncology specialist in Fort Worth, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Barrera performed 33,617 Medicare services across 2,812 unique beneficiaries.
Between the years covered by Open Payments, Dr. Barrera received a total of $16,002 from 79 pharmaceutical and/or device companies across 618 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Barrera is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 27% volume in TX
$16,002 industry payments
Medicare Practice Summary
Medicare Utilization ↗33,617
Medicare services
Top 27% in TX for hematology & oncology
2,812
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,769 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 14,300 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 6,010 | $0 | $3 |
| Pembrolizumab injection (Keytruda) | 5,400 | $42 | $135 |
| Denosumab injection (Prolia/Xgeva) | 960 | $16 | $65 |
| Dexamethasone injection (steroid) | 940 | $0 | $1 |
| Blood draw (venipuncture) | 840 | $8 | $20 |
| Complete blood count (CBC) with differential | 806 | $8 | $36 |
| Comprehensive metabolic blood panel | 720 | $10 | $64 |
| Office visit, established patient (30-39 min) | 611 | $88 | $368 |
| Injection, granisetron hydrochloride, 100 mcg | 360 | $0 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 181 | $22 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 160 | $98 | $707 |
| Ferritin level test (iron stores) | 155 | $13 | $60 |
| Iron level test | 155 | $6 | $27 |
| Iron binding capacity test | 155 | $8 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 105 | $46 | $313 |
| Injection, zoledronic acid, 1 mg | 104 | $7 | $431 |
| Office visit, established patient (20-29 min) | 101 | $61 | $250 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 90 | $91 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 84 | $1,163 | $4,802 |
| Microscopic examination for white blood cells with manual cell count | 82 | $4 | $22 |
| Complete blood count (CBC), automated | 82 | $6 | $34 |
| Drug injection, under skin or into muscle | 82 | $10 | $96 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 78 | $57 | $211 |
| New patient office visit, complex (60-74 min) | 71 | $160 | $709 |
| Immunoglobulin level test | 69 | $9 | $56 |
| Reticulated (young) platelet measurement | 68 | $35 | $143 |
| Vitamin B-12 level test | 67 | $15 | $76 |
| Ct scan of chest with contrast | 65 | $51 | $821 |
| Blood creatinine level | 65 | $5 | $31 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 57 | $71 | $70 |
| Hospital follow-up visit, moderate complexity | 55 | $62 | $247 |
| PSA test (prostate cancer screening) | 51 | $18 | $94 |
| CT scan of abdomen and pelvis with contrast | 50 | $162 | $1,067 |
| Measurement of immunoglobulin light chains | 48 | $17 | $60 |
| Administration of chemotherapy into vein, each additional hour | 45 | $19 | $161 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 44 | $324 | $1,722 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 36 | $15 | $100 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $42 | $344 |
| Injection of additional new drug or substance into vein | 33 | $11 | $108 |
| Injection, diphenhydramine hcl, up to 50 mg | 32 | $1 | $7 |
| Irrigation of implanted venous access drug delivery device | 31 | $16 | $114 |
| Unclassified drugs | 25 | $1 | $8 |
| Hospital follow-up visit, high complexity | 24 | $93 | $357 |
| CT scan of chest, without contrast | 17 | $42 | $686 |
| Infusion, normal saline solution , 1000 cc | 17 | $2 | $19 |
| Folic acid level test | 15 | $14 | $73 |
| Ct scan of abdomen and pelvis without contrast | 13 | $84 | $560 |
| Ct scan of soft tissue of neck with contrast | 12 | $50 | $658 |
| Lactate dehydrogenase (enzyme) level | 12 | $6 | $31 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.0% high complexity
85.6% medium
13.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,002
Total received (2018-2024)
Avg $2,286/year across 7 years
Top 24% in TX for hematology & oncology
79
Companies
618
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,773 (79.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,258 (7.9%)
Other
Charitable contributions, space rental, and other categories
$1,168 (7.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$804 (5.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,010
2023
$1,895
2022
$1,883
2021
$1,645
2020
$1,536
2019
$2,521
2018
$2,511
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,772
Novartis Pharmaceuticals Corporation
$1,567
Amgen Inc.
$1,175
PFIZER INC.
$943
Janssen Biotech, Inc.
$757
Takeda Pharmaceuticals U.S.A., Inc.
$536
Genentech USA, Inc.
$514
Celgene Corporation
$484
Astellas Pharma US Inc
$449
E.R. Squibb & Sons, L.L.C.
$421
Incyte Corporation
$360
Pharmacyclics LLC, An AbbVie Company
$351
Ipsen Biopharmaceuticals, Inc
$331
Seagen Inc.
$330
Rigel Pharmaceuticals, Inc.
$312
Merck Sharp & Dohme LLC
$286
Boehringer Ingelheim Pharmaceuticals, Inc.
$268
GlaxoSmithKline, LLC.
$249
Merck Sharp & Dohme Corporation
$234
Gilead Sciences, Inc.
$232
Janssen Scientific Affairs, LLC
$228
GENZYME CORPORATION
$225
Puma Biotechnology, Inc.
$200
SOBI, INC
$196
Exelixis Inc.
$189
Eisai Inc.
$176
ARRAY BIOPHARMA INC
$158
Adaptive Biotechnologies Corporation
$158
Regeneron Healthcare Solutions, Inc.
$149
Lilly USA, LLC
$145
EMD Serono, Inc.
$143
AbbVie Inc.
$137
Pharmacosmos Therapeutics Inc.
$134
Mirati Therapeutics, Inc.
$122
Kite Pharma, Inc.
$112
Verastem, Inc.
$108
Karyopharm Therapeutics Inc.
$106
TESARO, Inc.
$102
Seattle Genetics, Inc.
$95
Bayer HealthCare Pharmaceuticals Inc.
$91
Daiichi Sankyo Inc.
$88
Foundation Medicine, Inc.
$87
AbbVie, Inc.
$73
Teva Pharmaceuticals USA, Inc.
$68
MorphoSys, US Inc.
$67
Stemline Therapeutics Inc.
$66
Taiho Oncology, Inc.
$64
PharmaEssentia USA Corporation
$64
Kyowa Kirin, Inc.
$62
Deciphera Pharmaceuticals Inc.
$62
BeiGene USA, Inc.
$60
EISAI INC.
$50
CTI BioPharma Corp.
$49
Sobi, Inc
$44
ABBVIE INC.
$43
Lexicon Pharmaceuticals, Inc.
$39
Genmab U.S., Inc.
$35
INSYS Therapeutics Inc
$28
AVEO Pharmaceuticals, Inc.
$28
JAZZ PHARMACEUTICALS INC.
$25
Jazz Pharmaceuticals Inc.
$25
Myovant Sciences Inc.
$24
MENARINI SILICON BIOSYSTEMS, INC.
$23
SHIELD THERAPEUTICS INC
$22
SERVIER PHARMACEUTICALS LLC
$22
Alexion Pharmaceuticals, Inc.
$20
Janssen Pharmaceuticals, Inc
$20
Array BioPharma Inc.
$20
Tempus AI, Inc
$20
Bayer Healthcare Pharmaceuticals Inc.
$20
TerSera Therapeutics LLC
$19
ADC Therapeutics America, Inc.
$18
Acceleron Pharma, Inc.
$17
Epizyme, Inc.,
$17
G1 Therapeutics, Inc.
$15
Mylan Institutional Inc.
$14
MEDIVATION FIELD SOLUTIONS LLC
$14
Helsinn Therapeutics (U.S.), Inc.
$13
Blueprint Medicines Corporation
$12
Top 3 companies account for 28.2% of total payments
Associated products mentioned in payments ›
ACCRUFER · ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · AYVAKIT · Alecensa · Aliqopa · Aranesp · Avastin · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · CYRAMZA · Cabometyx · Cellsearch · Copiktra · DARZALEX · DAURISMO · DOPTELET · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Enhertu · Epkinly · Erleada · FOTIVDA · FOUNDATIONONE · FRUZAQLA · FULPHILA · Fabhalta · GAZYVA · GILOTRIF · HEMLIBRA · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MEKTOVI · MONJUVI · MONOFERRIC · MVASI · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PIQRAY · POTELIGEO · Perjeta · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Reblozyl · Revlimid · SANCUSO · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SUTENT · SYNDROS · Stivarga · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $48 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
42
Per 100K population
2.0
County median income
$81,905
Nearest hospital
TEXAS HEALTH HARRIS METHODIST HOSPITAL SOUTHWEST F
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Barrera is a mixed practice specialist, with above-average Medicare volume (top 27% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Barrera experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Barrera performed 14,300 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Barrera receive payments from pharmaceutical companies?
Yes. Dr. Barrera received a total of $16,002 from 79 companies across 618 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Barrera's costs compare to other hematology & oncology specialists in Fort Worth?
Dr. Barrera's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Barrera) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Fort Worth
Browse hematology & oncology specialists in Fort Worth ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology